Abstract：Objective To study the expression and diagnostic value of plasma miR-145 and miR-183 in children with lupus nephritis (LN). Methods A total of 92 children with LN who were admitted from January 2016 to May 2019 were enrolled as the LN group, among whom 17 had type II LN, 15 had type III LN, 36 had type IV LN, 18 had type V LN, and 6 had type VI LN. Forty healthy children who underwent physical examination were enrolled as the healthy control group. According to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), the 92 children with LN were further divided into a stable LN group with 34 children (SLEDAI score <10) and an active LN group with 58 children (SLEDAI score ≥ 10). RT-PCR was used to measure the expression of miR-145 and miR-183 in plasma. The receiver operating characteristic (ROC) curve was used to analyze the value of plasma miR-145, miR-183, and anti-dsDNA antibody in the diagnosis of LN. Pearson correlation analysis was used to investigate the correlation of the expression levels of miR-145 and miR-183 in plasma with laboratory markers. Results The LN, active LN, and stable LN groups had significantly higher levels of anti-dsDNA antibody, C-reactive protein, serum creatinine (Scr), and blood urea nitrogen (BUN) than the control group (P < 0.05). The active LN group had significantly higher SLEDAI score, anti-dsDNA antibody, Scr, and BUN than the stable LN group (P < 0.05). The LN, active LN, and stable LN groups had significantly lower levels of complement C3, complement C4, and serum albumin (Alb) than the control group (P < 0.05). The active LN group had a significantly lower level of Alb than the stable LN group (P < 0.05). The LN, active LN, and stable LN groups had significantly lower plasma levels of miR-145 and miR-183 than the control group (P < 0.01). The active LN group had significantly lower plasma levels of miR-145 and miR-183 than the stable LN group (P < 0.01). The children with difference types of LN had significantly lower plasma levels of miR-145 and miR-183 than the control group (P < 0.01), and the type V-VI group and the type IV group had significantly lower plasma levels of miR-145 and miR-183 than the type II-III group (P < 0.01). The ROC curve analysis showed that the optimal cut-off values of plasma miR-145, miR-183, and anti-dsDNA antibody were 1.05, 0.62, and 186.30 IU/mL respectively, in the diagnosis of LN, and the combination of these three indices had the largest area under the ROC curve of 0.896 (95%CI:0.835-0.955), with a sensitivity of 90.5% and a specificity of 84.2%. In the children with LN, the plasma levels of miR-145 and miR-183 were negatively correlated with SLEDAI score, anti-dsDNA antibody, Scr, and BUN (P < 0.05) and were positively correlated with complement C3, complement C4, and Alb (P < 0.05). Conclusions There are significant reductions in the expression levels of miR-145 and miR-183 in plasma in children with LN, which are correlated with the activity level and pathological typing of LN. Combined measurement of miR-145, miR-183, and anti-dsDNA antibody has a high value in the diagnosis of LN.
LIN Lie-Ju,MAI Lang-Jun,CHEN Guang et al. Expression and diagnostic value of plasma miR-145 and miR-183 in children with lupus nephritis[J]. CJCP, 2020, 22(6): 632-637.
Raimbourg Q, Daugas É. Lupus nephritis[J]. Nephrol Ther, 2019, 15(3):174-189.
[2]
Kay SD, Carlsen AL, Voss A, et al. Associations of circulating cell-free microRNA with vasculopathy and vascular events in systemic lupus erythematosus patients[J]. Scand J Rheumatol, 2019, 48(1):32-41.
[3]
Navarro Quiroz E, Navarro Quiroz R, Pacheco Lugo L, et al. Integrated analysis of microRNA regulation and its interaction with mechanisms of epigenetic regulation in the etiology of systemic lupus erythematosus[J]. PLoS One, 2019, 14(6):e0218116.
[4]
Lu MC, Lai NS, Chen HC, et al. Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis[J]. Clin Exp Immunol, 2013, 171(1):91-99.
[5]
Wang Z, Heid B, Dai R, et al. Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice[J]. Lupus Sci Med, 2018, 5(1):e000290.
[6]
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8):2677-2686.
[7]
Satish S, Deka P, Shetty MS. A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system[J]. J Lab Physicians, 2017, 9(3):149-155.
[8]
Su YJ, Lin IC, Wang L, et al. Next generation sequencing identifies miRNA-based biomarker panel for lupus nephritis[J]. Oncotarget, 2018, 9(46):27911-27919.
[9]
Wu S, Wang J, Li F. Dysregulation of PTEN caused by the underexpression of microRNA-130b is associated with the severity of lupus nephritis[J]. Mol Med Rep, 2018, 17(6):7966-7972.
[10]
Tian S, Liu X, Fan Q, et al. Microarray expression and functional analysis of circular RNAs in the glomeruli of NZB/W F1 mice with lupus nephritis[J]. Exp Ther Med, 2019, 18(4):2813-2824.
[11]
Navarro-Quiroz E, Pacheco-Lugo L, Navarro-Quiroz R, et al. Profiling analysis of circulating microRNA in peripheral blood of patients with class IV lupus nephritis[J]. PLoS One, 2017, 12(11):e0187973.
[12]
Zheng CZ, Shu YB, Luo YL, et al. The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis[J]. Eur Rev Med Pharmacol Sci, 2017, 21(5):1041-1048.
Zhang Y, Wang Y. The correlation of plasma microRNA-200 family expressions with risk and disease severity of lupus nephritis[J]. Eur Rev Med Pharmacol Sci, 2018, 22(10):3118-3125.
Cai Z, Xiang W, Peng X, et al. MicroRNA-145 involves in the pathogenesis of renal vascular lesions and may become a potential therapeutic target in patients with juvenile lupus nephritis[J]. Kidney Blood Press Res, 2019, 44(4):643-655.
